相关临床试验
492
31 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1826
进行中（未招募）
17
3.5%
已完成
265
53.9%
Enrolling By Invitation
1
0.2%
尚未招募
13
2.6%
招募中
47
9.6%
暂停
4
0.8%
终止
68
13.8%
撤回
77
15.7%
暂无批准数据
- The University of Kentucky Markey Cancer Center became the first U.S. site to treat a patient with Alveltamig (ZG006), a novel trispecific T-cell engager immunotherapy for small cell lung cancer in late October. - Alveltamig features an enhanced design with three binding arms compared to FDA-approved bispecific tarlatamab, potentially offering stronger cancer cell-immune cell connections for patients whose disease has progressed. - The first patient experienced no side effects from initial dosing and tolerated a second treatment well, with the therapy showing potential activity against brain metastases common in small cell lung cancer. - The Phase 1 trial follows successful tolerability data from China and will enroll patients at six U.S. sites to evaluate this next-generation immunotherapy approach.
- Only 16% of high-risk myelodysplastic syndrome patients receive indicated hypomethylating agent therapy, despite guidelines recommending treatment for all patients in this category. - Younger, white, male patients are significantly more likely to receive treatment, while patients over 74, females, and Black patients face substantial disparities in access to care. - Half of treated patients discontinue therapy by cycle 6 and fail to complete minimum recommended treatment cycles, compromising therapeutic outcomes. - The study analyzed 7,935 Medicare patients and found widespread non-adherence to established treatment guidelines across multiple demographic groups.
